Simultaneous application of the vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 and ionizing radiation does not further reduce the growth of canine oral melanoma xenografts in nude mice

被引:3
|
作者
Inteeworn, Natalie [1 ]
Ohlerth, Stefanie
Hoepfl, Gisele
Guscetti, Franco
Bley, Carla Rohrer
Wergin, Melanie C.
Roos, Malgorzata
Gassmann, Max
Kaser-Hotz, Barbara
机构
[1] Univ Zurich, Vetsuisse Fac, Sect Diagnost Imaging & Radiooncol, CH-8006 Zurich, Switzerland
[2] Univ Zurich, Vetsuisse Fac, Inst Vet Physiol, CH-8006 Zurich, Switzerland
[3] Univ Zurich, Vetsuisse Fac, Inst Vet Pathol, CH-8006 Zurich, Switzerland
[4] Univ Zurich, Dept Biostat, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
来源
VETERINARY JOURNAL | 2007年 / 173卷 / 03期
关键词
melanoma; xenograft; canine; PTK787/ZK; 222584; radiotherapy; power Doppler ultrasonography; pO(2);
D O I
10.1016/j.tvjl.2007.03.001
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
PTK787/ZK 222584 is an inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. In this study, the effectiveness of PTK787/ZK 222584 and radiation on canine oral melanoma xenografts was assessed. Xenografts were treated with radiotherapy (4 x 6 Gy), or with PTK787/ZK 222584, or with a combination of both. Treatment efficacy was assessed using a tumour growth delay assay, serial power Doppler and pO(2) measurements during and after therapy. There was a significant growth delay for the group treated with radiation alone and for the combined treatment group. However, tumour growth delay was similar in both groups. Tumours were hypoxic before irradiation and no significant re-oxygenation occurred during therapy. In all tumours, vascularity and perfusion were significantly lower at the end of the study but no significant differences in perfusion, vascularity and oxygenation status were observed between and within treatment groups. The combination of PTK787/ZK 222584 and radiotherapy did not perform better than radiotherapy alone in this model. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:564 / 570
页数:7
相关论文
共 37 条
  • [31] Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors
    Dy, G. K.
    Croghan, G. A.
    Qi, Y.
    Glockner, J.
    Hanson, L.
    Roos, M.
    Tan, A. D.
    Molina, J. R.
    Adjei, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model
    Drevs, J
    Hofmann, I
    Hugenschmidt, H
    Wittig, C
    Madjar, H
    Müller, M
    Wood, J
    Martiny-Baron, G
    Unger, C
    Marmé, D
    CANCER RESEARCH, 2000, 60 (17) : 4819 - 4824
  • [33] Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
    Brander, Danielle
    Rizzieri, David
    Gockerman, Jon
    Diehl, Louis
    Shea, Thomas Charles
    Decastro, Carlos
    Moore, Joseph O.
    Beaven, Anne
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2627 - 2630
  • [34] Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
    Hecht, J. Randolph
    Trarbach, Tanja
    Hainsworth, John D.
    Major, Pierre
    Jager, Elke
    Wolff, Robert A.
    Lloyd-Salvant, Katherine
    Bodoky, Gyorgy
    Pendergrass, Kelly
    Berg, William
    Chen, Bee-Lian
    Jalava, Tarja
    Meinhardt, Gerold
    Laurent, Dirk
    Lebwohl, David
    Kerr, David
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 1997 - 2003
  • [35] A phase I trial of a combination of the mTOR Inhibitor Everolimus (RAD001) and two schedules of the vascular enclothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK 222584) in patients (pts) with advanced solid tumors
    Dy, G.
    Croghan, G.
    Furth, A.
    Reid, J.
    Hanson, L.
    Roos, M.
    Tan, A.
    Adjei, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 15 - 15
  • [36] Phase I Pharmacokinetic Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787) Plus Imatinib and Hydroxyurea for Malignant Glioma
    Reardon, David A.
    Egorin, Merrill J.
    Desjardins, Annick
    Vredenburgh, James J.
    Beumer, Jan H.
    Lagattuta, Theodore F.
    Gururangan, Sridharan
    Herndon, James E., II
    Salvado, August J.
    Friedman, Henry S.
    CANCER, 2009, 115 (10) : 2188 - 2198
  • [37] Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases:: Results from two phase I studies
    Morgan, B
    Thomas, AL
    Drevs, J
    Hennig, J
    Buchert, M
    Jivan, A
    Horsfield, MA
    Mross, K
    Ball, HA
    Lee, L
    Mietlowski, W
    Fuxius, S
    Unger, C
    O'Byrne, K
    Henry, A
    Cherryman, GR
    Laurent, D
    Dugan, M
    Marmé, D
    Steward, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3955 - 3964